CAR-T manufacturing reduces heterogeneity between CIDP and multiple myeloma patient-derived T cells.

Against CD19-positive NALM-6 targets, a trend toward reduced killing was observed in CIDP-CAR-T cells ( p = 0.104), though this did not reach statistical significance (Figure 5 G) .

also in 111,027 other papers

Furthermore, MM patients showed a trend toward higher proportions of PD1+Tim3+ exhausted and terminally differentiated T cells compared to HCs, even though it did not meet the threshold for significance (Figure 1 G-H) .

also in 53,322 other papers